Objective: To compare the efficacy and tolerability of mibefradil (−11.5 ± 8.2 mm Hg) and 5/10 mg amlodipine (−13.2 ± 7.9 mm Hg). The number of patients with normibefradil and amlodipine in patients with uncomplicated mild-to-moderate essential hypertension. malised SDBP (р90 mm Hg) increased 23.3% in the mibefradil group and 19.5% in the amlodipine group Design: A double-blind, randomised, parallel group multicentre trial.
Introduction
cology distinguishes mibefradil from existing CAs in Calcium antagonists (CAs) have gained widespread two ways: (1) mibefradil binds to a unique receptor acceptance as first-line therapy in the management site that appears to overlap the verapamil, the diltiaof essential hypertension.
1 Amlodipine, a dihydrozem and the SR3557 sites, resulting in competitive pyridine derivative with a pharmacokinetic profile displacement of the three compounds without suitable for once-daily dosing, represents an affecting the dihydropyridine binding site; 5 (2) it improvement over short-acting CAs. Clinical studies blocks both L-and T-type calcium channels, in hypertension have confirmed that 5-to 10-mg whereas other CAs, including amlodipine, block doses of amlodipine are effective in reducing sysonly the L-type channel. 6 The pharmacokinetic featolic and diastolic blood pressure (SBP/DBP) tures of mibefradil include a high bioavailability (up throughout the 24-h dosing period, 2,3 and the drug to 90%) 7 and a long half-life (17-25 h). 8 Clinical is claimed to be well tolerated by patients with mildstudies have shown that once-daily treatment with to-moderate hypertension. 4 mibefradil is effective in the treatment of hypertenMibefradil (Ro 40-5967) is a novel CA that belongs sion 9 and chronic stable angina pectoris, 10 and like to a new structural class of benzimidazolyl-substiamlodipine, mibefradil is not associated with a reflex increase in neurohormones or negative inotropic effects. [11] [12] [13] [14] However, unlike amlodipine, decrease in heart rate.
9, 10, 15 whether differences in the pharmacologic features of 4-week randomized withdrawal period, during which they either remained on active treatment these two long-acting CAs, mibefradil and amlodipine, translate into meaningful therapeutic differ-(mibefradil 100 mg or amlodipine 10 mg) or were switched to placebo. To ensure blinding, trial mediences when these drugs are used as treatment of mild-to-moderate essential hypertension.
cation consisted of identical (size 0) gelatin capsules containing either mibefradil, amlodipine or placebo. Patients were excluded from participation if they
Materials and methods
had malignant or secondary hypertension, major systemic diseases (except for diabetes mellitus or Trial design and patient selection well-controlled hypothyroidism), or a history of This was a multicentre, double-blind, randomised, alcohol or drug abuse. Concomitant use of mediforced-titration, parallel-design trial which comcations affecting BP or interfering with the effects of pared the antihypertensive effectiveness, safety and calcium antagonists was not allowed. tolerability of once-daily administration of 50/100 mg mibefradil and 5/10 mg amlodipine in patients with mild-to-moderate essential hypertenStudy variables sion. The study was performed at 15 sites in nine Patients returned to the clinic weekly during the countries; it was approved by the local ethics comrun-in period, every 2 weeks during the first 12 mittees and conducted according to the principles weeks of active treatment, and every week during of the Declaration of Helsinki as amended in Tokyo, the last 4 weeks of the trial. At each visit, trough Venice, and Hong Kong.
(21-27 h postdose) BP and heart rate were measured Male and female subjects, aged 20-70 years, with prior to the morning's dose of study medication. uncomplicated, mild-to-moderate essential hyperTolerability of trial medication was assessed by tension were screened after providing informed conrecording adverse events at each visit. A resting 12-sent and, if eligible, were asked to discontinue all lead electrocardiogram (ECG) was performed at current antihypertensive medications. The trial screening and every 4 weeks during the trial, blood design is presented schematically in Figure 1 . After samples were obtained for determination of haema-4 weeks of a single-blind, placebo run-in period, tology and clinical chemistry laboratory analyses, patients were considered eligible for entry into the and urine was collected for analysis at screening, at double-blind period if, at the end of the third and baseline and after 12 and 16 weeks of active treatfourth weeks of the run-in period, their trough (24 ment. A complete physical examination was per-± 3 h after the last dose) sitting diastolic blood presformed at the screening and the final study visits. sure (SDBP) was between 95 and 114 mm Hg and their compliance was at least 80% (capsule counting). Those who qualified were randomised to Statistical analyses receive either 50 mg mibefradil or 5 mg amlodipine once daily for 4 weeks followed by a forced titration
The primary analysis of study parameters was conto 100 mg mibefradil or 10 mg amlodipine for 8 ducted using the intent-to-treat (ITT) population; weeks, respectively. At Week 12, patients entered a that is, patients who received one or more doses of randomised trial medication and had a baseline and at least one subsequent BP measurement that was obtained 21-27 h postdose. The primary efficacy parameters were the change from baseline in trough SDBP at Week 12 (mibefradil vs amlodipine) and at Week 16 (mibefradil vs placebo and amlodipine vs placebo). An analysis of covariance (ANCOVA) was used to test the statistical equivalence of both treatments at Week 12. The linear model contained treatment, centre and treatment-by-centre as fixed factors and baseline SDBP as a covariate. The equivalence of the BP-lowering effects of mibefradil and amlodipine was tested as follows: if the pre-defined interval of ±3 mm Hg contained completely the two-sided 90% confidence interval for the effect of mibefradil vs amlodipine, then the two treatments were determined to be statistically equivalent (Westlake procedure). 16 The study had a Ͼ80% power to show equivalence at Week 12 and a Ͼ80% power to detect a difference in DBP of 5 mm Hg vs placebo at the end of the withdrawal period. Least square means were used to estimate treatment effects. The BP at the end of the treatment period was used as a second covariate for the analysis of the primary parameters at the end of the withdrawal period. A significant Results BL = baseline; SDBP = sitting diastolic blood pressure.
Patient characteristics
Values are mean ± s.d.
Of the 279 patients with mild-to-moderate hypertension who entered the placebo run-in period, 40 lar to those of the main analysis, with a treatment patients did not qualify for randomisation. The difference between the two groups of 1.0 mm Hg. remaining 239 patients were randomised into active By Week 12, SDBP was normalised (р90 mm Hg) treatment (mibefradil: 120 patients; amlodipine:
in 58.3% and 55.5% of the patients treated with 119 patients).
mibefradil and amlodipine, respectively, and more Except for the male-female ratio, which was than 70% of the patients in each treatment group slightly higher in the mibefradil group than in the had a decrease in SDBP from baseline of у10 mm Hg amlodipine group, the two treatment groups were (Figure 2 ). SDBP was normalised in 35% and 36% comparable with respect to their demographic of the patients treated with mibefradil 50 mg and characteristics (Table 1) .
amlodipine 5 mg, respectively, at Week 4 of active treatment.
Antihypertensive efficacy of mibefradil vs
The mean change from baseline to Week 12 in amlodipine SSBP at trough was slightly larger in the amlodipine group (−20.0 ± 16 mm Hg from a baseline of 163.7 ± Except for five mibefradil-treated patients who did 18.0 mm Hg) than in the mibefradil group (−15.2 ± not have any valid post-randomisation trough BP 14.8 mm Hg from a baseline of 161.1 ± 17.9 mm Hg), measurements, data from all randomised patients with an estimated treatment difference of 3.5 mm Hg were included in the efficacy analyses (ITT population) for the 12-week active treatment period (mibefradil: 115 patients; amlodipine: 119 patients). Clinically relevant reductions from baseline in trough SDBP were observed after 12 weeks of treatment with both treatment regimens (−11.5 ± 8.2 mm Hg with mibefradil 50/100 mg and −13.2 ± 7.9 mm Hg with amlodipine 5/10 mg). The two compounds were found to be statistically equivalent according to the Westlake procedure 16 with a treatment difference of 1.3 mm Hg ( Table 2) . As the gender distribution between the two groups was not the same and the decrease in SDBP in women was slightly larger than that in men in both treatment groups, a further analysis was done in which gender was taken into consideration in the statistical model. The results of this further analysis were simi- (P = 0.032). The time course of the decline in SDBP gradual increase in SDBP (Figure 4) , indicating a lack of hypertensive rebound with these two comand SSBP at trough over the 12-week active treatment period was similar for mibefradil and amlodipounds. While the withdrawal of mibefradil therapy was associated with a gradual increase in sitting pine (Figure 3) .
Sitting heart rate was decreased by an average of heart rate (from 68.4 ± 10.9 bpm at Week 12 to 71.0 ± 7.5 bpm at Week 16), cessation of amlodipine was 5.5 ± 11 beats per minute (bpm) from baseline following 12 weeks of treatment with mibefradil. In associated with a slight decrease in sitting heart rate (from 76.0 ± 10.9 bpm at Week 12 to 72.6 ± 8.9 bpm contrast, the mean change from baseline to Week 12 in sitting heart rate in the amlodipine group was at Week 16). negligible (+0.7 ± 11 bpm).
Safety and tolerability Treatment effects during the randomised placebo
Of the patients receiving active treatment for up to withdrawal period 16 weeks, a total of 51 (42.5%) on mibefradil and 52 (43.7%) on amlodipine reported at least one adverse Efficacy analyses of the BP response during the withdrawal period were based upon the 210 patients event (AE) judged by the investigators to be either remotely, possibly or probably related to trial treatwho had valid trough BP measurements at baseline and during the randomised withdrawal period of the ment. The incidence of the most frequent AEs is summarised in Table 4 . Leg oedema was the most trial (Weeks 12-16). These included 53 patients who continued therapy with 100 mg mibefradil, 52 who common AE among patients receiving amlodipine, reported by 40 patients (33.6%). In contrast, only continued therapy with 10 mg amlodipine, 50 who were switched to placebo from mibefradil, and 55 five patients (4.2%) receiving mibefradil reported leg oedema (P Ͻ 0.01). Similarly, during the lowwho were switched to placebo from amlodipine.
The mean changes from baseline to end of the randose treatment period (mibefradil 50 mg and amlodipine 5 mg), none of the mibefradil patients reported domised withdrawal period in trough SDBP observed in each treatment group are summarised leg oedema, while 11 of the amlodipine patients (9%) complained of leg oedema. The incidence of in Table 3 . Statistically significant (P Ͻ 0.001) and clinically relevant larger reductions in SDBP were this AE was higher in women (25 of 57; 44.0%) than in men (15 of 62; 24.0%) within the amlodipine observed in the mibefradil-and amlodipine-treated patients when compared with their corresponding group. Dyspepsia was the most frequent AE in the mibefradil-treated patients (11.7% vs 0.8% in the placebo groups. The abrupt cessation of mibefradil and amlodipine therapies was associated with a amlodipine group). During the randomised withdrawal period from active drug to placebo, new AEs were reported by two patients in each active treatment group (those who continued treatment with either mibefradil or amlodipine). In contrast, a greater number of AEs were experienced by patients switched from amlodipine to placebo therapy (13 AEs in nine patients; 16.4%) than by patients switched from mibefradil to placebo therapy (two AEs in two patients; 3.9%). Headache (n = 4), fatigue (n = 2), and palpitation (n = 2) were the most common complaints in those switched from amlodipine to placebo. Worsening of hypertension was reported in one patient from each treatment group that was switched to placebo.
During active treatment with mibefradil, eight patients discontinued for AEs. Thirteen patients discontinued treatment with amlodipine because of AEs; 12 cases were due to leg oedema. There were three reports of serious AEs during the trial; two were considered unrelated to trial treatment (renal colic in an amlodipine patient, and a cerebrovascular accident that led to the withdrawal of one mibefradil patient), and one (retinal haemorrhage) was considered remotely related to mibefradil treatment.
Based on electrocardiographic data, mibefradil treatment was associated with a modest reduction in heart rate (−6.4 ± 9.0 bpm), a slight increase in the patients were force-titrated from 50 to 100 mg and from 5 to In contrast, the heart rate and PQ interval were cardia (a decrease in heart rate to Ͻ55 bpm with a change from baseline of Ͼ10 bpm) was the most common treatment-emergent ECG change in the mibefradil group, observed in 14 (12%) patients as compared with three (3%) patients in the amlodipine group. First-degree atrioventricular (AV) block was observed in seven (6%) mibefradil and two (2%) amlodipine patients. Only one patient in the mibefradil group was discontinued from the trial because of an ECG change (sinus bradycardia with heart rate of 42 bpm).
No consistent pattern of mean changes or individual abnormalities in any laboratory parameter was observed with either treatment group.
Discussion
The results of the present study demonstrate that once-daily administration of 50-100 mg mibefradil for 12 weeks resulted in a clinically meaningful reduction in SDBP that averaged −11.5 mm Hg and was statistically equivalent to that seen after 12 weeks of once-daily treatment with 5-10 mg amlodipine. The therapeutic response rates (reduction in SDBP у10 mm Hg from baseline) achieved for both compounds were comparable (73% and 74% for mibefradil and amlodipine, respectively). Approximately one-third of the patients achieved normalis- was almost doubled at Week 12 following forced titration to the highest recommended doses of both compounds (100 mg mibefradil and 10 mg amlodipine).
The time course of antihypertensive effect was Table 4 Most frequent adverse events (AE) reported by Ͼ2% of similar for mibefradil and amlodipine, and neither with amlodipine. This differing effect of the two drugs on heart rate is of potential importance, as the patient discontinued therapy because of a reduced heart rate. results of several epidemiological studies demonstrate that a lower heart rate is associated with a reduction in cardiovascular morbidity and morConclusion tality, especially in patients with cardiovascular complications.
17-21
This assumption, however,
The results of this trial indicate that the pharmaconeeds to be evaluated in large, prospective studies.
logically novel long-acting CA, mibefradil, in conWhile mibefradil and amlodipine were comtrast to amlodipine, is better tolerated, with a lower parable in their antihypertensive efficacy, their incidence of leg oedema, which may lead to tolerability profiles were markedly different.
improved patient compliance and hypertension Approximately one-third of the patients treated with management. Unlike amlodipine, treatment with amlodipine reported leg oedema, compared to fewer mibefradil is associated with a slight decrease in than 5% of those receiving mibefradil. Ten per cent heart rate, which may prove clinically beneficial for of the patients in the amlodipine group were hypertensive patients with atherosclerotic cardioprematurely discontinued as a result of leg oedema, vascular complications. as opposed to the mibefradil group, where no patient withdrew due to leg oedema. Within the Acknowledgements amlodipine group, leg oedema was reported much more frequently in women (44%) than in men
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